Progressive multifocal leukoencephalopathy epidemiology and demographics

Jump to navigation Jump to search


Progressive multifocal leukoencephalopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Progressive multifocal leukoencephalopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Progressive multifocal leukoencephalopathy epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Progressive multifocal leukoencephalopathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Progressive multifocal leukoencephalopathy epidemiology and demographics

CDC on Progressive multifocal leukoencephalopathy epidemiology and demographics

Progressive multifocal leukoencephalopathy epidemiology and demographics in the news

Blogs on Progressive multifocal leukoencephalopathy epidemiology and demographics

Progressive multifocal leukoencephalopathy

Risk calculators and risk factors for Progressive multifocal leukoencephalopathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

About 2-5% of AIDS patients develop PML. It is unclear why PML occurs more frequently in AIDS than in other immunosuppressive conditions; some research suggests that the effects of HIV on brain tissue, or on JCV itself, make JCV more likely to become active in the brain and increase its damaging inflammatory effects (Berger, 2003).

There are case reports of PML being caused by pharmacological agents, although there is some speculation this could be due in part to the existing impaired immune response or 'pharm combos' rather than individual drugs. Rituxan and Natalizumab (branded Tysabri).

References


Template:WH Template:WS